AN2 Therapeutics, Inc. (ANTX) AI Stock Analysis

• Market Cap: $32.29M
• Dividend Yield: N/A
• Average Volume (3M): 260.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: N/A
• EPS Growth: 38.98%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.35
• Shares Outstanding: 30,175,720
• 10 Day Avg. Volume: 163,216
• 30 Day Avg. Volume: 260,417
• PEG Ratio: 0.00
• Price to Book (P/B): 59.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -116.09
• Enterprise Value/Market Cap: 8.79
• Enterprise Value/Revenue: 1.77K
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.19
• 1Y Price Target: $1.67
• Price Target Upside: 56.07% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 34 Underperform
• Price Target: ―

AN2 Therapeutics, Inc. exhibits significant financial challenges typical for its stage, including lack of revenue and continuous cash burn, with no profitability in sight. The stable balance sheet provides some cushion, but the absence of revenue growth and reliance on external funding are concerning. Technically, the stock shows neutral trends, with no clear directional momentum. Valuation remains speculative, given the negative P/E ratio and absence of dividends. Overall, while the financial structure is stable, the company's prospects hinge on successful product development and strategic partnerships.

Positive Factors

Financial Stability

Cash, cash equivalents, and investments totaled $78.5M, anticipated to fund operations into 2028.

Pipeline and Innovation

The company is on track for announcing one or more oncology development candidates from its boron-chemistry discovery platform that it believes can be best- and/or first-in-class for targeting solid tumors.

Regulatory Outlook

The FDA is likely to accept Quality of Life measures as an efficacy endpoint, which is beneficial for the drug's approval process.

Negative Factors

Clinical Efficacy

The key secondary endpoint of sputum culture conversion was not met; 6-month culture conversion was similar between arms.

Clinical Trials

The final shoe has dropped for AN2 Therapeutics' epetraborole program in refractory MAC lung disease, as the EBO-301 Ph.3 study missed the primary endpoint.

Program Termination

AN2 terminated both the Ph2 and Ph3 parts of the EBO-301 trial.

AN2 Therapeutics, Inc. Business Overview & Revenue Model

Company Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

How the Company Makes Money

AN2 Therapeutics makes money primarily through the development and eventual commercialization of its proprietary drug candidates. The company's revenue model is based on achieving successful clinical trial results that lead to regulatory approvals, which would then allow for the commercialization and sale of its therapeutic products. Key revenue streams include potential product sales, licensing agreements, and partnerships with other pharmaceutical companies. These partnerships may involve collaboration on research and development or co-marketing arrangements that provide upfront payments, milestone payments, and royalties. Additionally, the company may also secure funding through strategic alliances, grants, and investor funding to support its drug development programs.

AN2 Therapeutics, Inc. Financial Statement Overview

Summary

AN2 Therapeutics, Inc. faces typical challenges for a biotech firm at its stage, including lack of revenue and dependence on external funding. While the balance sheet shows a strong equity position and no debt, persistent negative cash flows and losses underscore the need for successful product development or partnerships to achieve financial sustainability.

Income Statement

AN2 Therapeutics, Inc. shows no revenue generation, which is typical for early-stage biotech companies. The company has consistently reported negative EBIT and net income, indicating operational and net losses. A lack of revenue growth and continuous losses highlight significant challenges in achieving profitability.

Balance Sheet

The company's financial structure is relatively stable with no debt and positive stockholders' equity, providing a solid equity base. However, the absence of revenue raises concerns about the sustainability of this financial position without additional financing.

Cash Flow

Negative operating and free cash flows are consistent, reflecting cash burn typical for R&D-focused biotech firms. The reliance on financing cash flow indicates dependence on external funding to support operations, which poses a risk if future funding is not secured.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	-77.00K	0.00	0.00
	EBIT
-50.03M	-54.55M	-69.64M	-42.26M	-21.57M	-7.28M
	EBITDA
-47.80M	-51.32M	4.90M	-42.26M	-21.57M	-6.32M
	Net Income Common Stockholders
-45.35M	-51.32M	-64.73M	-40.96M	-21.54M	-13.60M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
67.06M	83.62M	107.30M	96.06M	58.55M	4.07M
	Total Assets
81.34M	92.09M	138.74M	102.56M	65.32M	4.23M
	Total Debt
0.00	0.00	0.00	53.00K	0.00	0.00
	Net Debt
-19.98M	-21.35M	-15.65M	-27.17M	-12.10M	-4.07M
	Total Liabilities
8.01M	10.24M	14.04M	7.19M	112.73M	24.55M
	Stockholders Equity
73.33M	81.85M	124.70M	95.37M	-47.41M	-20.32M
Cash Flow		Free Cash Flow
-42.29M	-49.26M	-53.29M	-33.46M	-20.48M	-5.36M
	Operating Cash Flow
-42.29M	-49.26M	-53.29M	-33.46M	-20.48M	-5.36M
	Investing Cash Flow
37.49M	54.59M	-43.28M	-21.77M	-50.02M	0.00
	Financing Cash Flow
88.00K	372.00K	84.99M	70.36M	78.53M	3.84M

AN2 Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANTX, the sentiment is Negative. The current price of 1.07 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.20, and below the 200-day MA of 1.21, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 38.94 is Neutral, neither overbought nor oversold. The STOCH value of 52.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANTX.

AN2 Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
SPRO	48 Neutral	$161.58M	10.83	-107.28%	―	-71.68%	-397.61%
DYAI	46 Neutral	$28.29M	―	-214.26%	―	20.58%	15.90%
XFOR	44 Neutral	$17.66M	1.26	121.75%	―	―	―
OTLK	38 Underperform	$78.85M	―	<0.01%	―	―	-29.01%
ITRM	35 Underperform	$39.84M	―	607.06%	―	―	55.67%
ANTX	34 Underperform	$32.29M	―	-49.32%	―	―	38.98%

AN2 Therapeutics, Inc. Corporate Events

AN2 Therapeutics Faces Setback in Phase 3 Study

AN2 Therapeutics announced the results of the Phase 3 portion of the EBO-301 study, which did not meet its primary endpoint for improving quality of life in patients with severe MAC lung disease. Despite this setback, the company remains optimistic about its boron chemistry pipeline, with plans to advance clinical programs in infectious diseases and oncology. The company is focusing on developing treatments for chronic Chagas disease and melioidosis, as well as leveraging its boron chemistry to create oncology compounds. AN2 Therapeutics has extended its cash runway into 2028 and is implementing strategic measures to optimize operations and enhance shareholder value.

Spark’s Take on ANTX Stock

According to Spark, TipRanks’ AI Analyst, ANTX is a Underperform.

AN2 Therapeutics, Inc. exhibits significant financial challenges typical for its stage, including lack of revenue and continuous cash burn, with no profitability in sight. The stable balance sheet provides some cushion, but the absence of revenue growth and reliance on external funding are concerning. Technically, the stock shows neutral trends, with no clear directional momentum. Valuation remains speculative, given the negative P/E ratio and absence of dividends. Overall, while the financial structure is stable, the company’s prospects hinge on successful product development and strategic partnerships.

To see Spark’s full report on ANTX stock, click here.